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Abstract

14-3-3σ, a gene upregulated by p53 in response to DNA damage, exists as part of a
positive-feedback loop which activates p53 and is a human cancer epithelial marker
downregulated in various cancer types. 14-3-3σ levels are critical for maintaining p53
activity in response to DNA damage and regulating signal mediator such as Akt. Here,
we identify Mammalian Constitutive Photomorphogenic 1 (COP1) as a novel E3 ubiquitin
ligase for targeting 14-3-3σ through proteasome degradation. We show for the first time
that COP9 signalosome subunit 6 (CSN6) associates with COP1 and is involved in 14-33σ ubiquitin-mediated degradation. Mechanistic studies show that CSN6 expression
leads to stabilization of COP1 through reducing COP1 self-ubiquitination and
decelerating COP1’s turnover rate. We also show that CSN6-mediated 14-3-3σ
ubiquitination is compromised when COP1 is knocked down. Thus, CSN6 mediates 143-3σ ubiquitination through enhancing COP1 stability. Subsequently, we show that CSN6
causes 14-3-3σ downregulation, thereby activating Akt and promoting cell survival by
suppressing FOXO, an Akt target, transcriptional activity. Also, CSN6 overexpression
leads to increased cell growth, transformation and promotes tumorigenicity. Significantly,
14-3-3σ expression can correct the abnormalities mediated by CSN6 expression. These
data suggest that the CSN6-COP1 axis is involved in 14-3-3σ degradation, and that
deregulation of this axis will promote cell growth and tumorigenicity.
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CHAPTER 1. INTRODUCTION

1.1. COP9 signalosome 6 (CSN6), a multiprotein complex
The ubiquitin-proteasome pathway is important for controlling the abundance of
proteins and plays an essential role in maintaining normal cellular functions.
Dysregulation of ubiquitin-mediated proteolysis results in the development of a variety of
human cancers (1). The evolutionarily conserved Constitutive Photomorphogenesis 9
Signalosome (CSN) was originally identified from plant (Arabidopsis) mutants that mimic
light-induced seedling development when grown in the dark (2-4). Mammalian COP9
signalosome contains eight subunits (CSN1-CSN8), which share sequence homology
with subunits of the ‘lid’ complex of the 26S proteasome (5). Because of the homology,
the COP9 signalosome has been postulated to play a role in protein degradation. CSN6
and CSN5 are the only two subunits that contain an MPN (Mpr1p and Pad1p N-terminal)
domain (6, 7), which will have impact on Cullin-Ring Ligases (CRL) (8, 9). CSN5 has a
MPN domain containing JAMM (JAB1/MPN/Mov34) or MPN+ motif linked to the
metalloprotease motif (EXnHXHX10D) that can deneddylate Cullin (9), a process
important for regulating CRL activity. By comparison, CSN6 is not recognized to have
JAMM motif and thus its function remain obscure.

1.2. Constitutive Photomorphogenic 1 (COP1), an E3 ubiquitin ligase
Mammalian Constitutive Photomorphogenic 1 (COP1) is an evolutionarily conserved E3
ubiquitin ligase containing RING-finger, coiled-coil, and WD40-repeat domains (10).
Through association with the COP9 signalosome, COP1 has been identified as a crucial
mediator to block photomorphogenesis in the dark through the ubiquitinated proteasomal
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degradation of light-induced transcription factor HY5 (11)(12). In mammalian cells, the
ubiquitinated targets of COP1 include stress-responsive transcription factors p53 (13)
and c-JUN (14-16), as well as acetyl-coA carboxylase (17), transducer of regulated
CREB activity 2 (TORC2, a glucose metabolite regulator) (18) and nucleosome
remodeling factor MTA1 (19). COP1 is overexpressed in cancers, but whether COP1
targets any tumor suppressor protein for degradation during tumorigenesis remains
elusive.

1.3. 14-3-3σ, a tumor suppressor gene
The 14-3-3 proteins are a family of evolutionarily conserved regulatory chaperone
molecules involved in many diverse physiological functions, including signal transduction,
stress response, apoptosis and cell cycle checkpoint regulation (20, 21). In mammals, the
14-3-3 family comprises seven isoforms β, ε, γ, ζ, η, σ and τ, which are widely expressed
in various tissues and exert their biological functions by directly binding to
phosphoproteins containing the consensus motifs RX(Y/F)XpSXP or RSXpSXP (22).
Binding by 14-3-3 proteins mediates stability and/or subcellular localization of target
proteins (23). 14-3-3σ (also known as Stratifin) was originally characterized as a human
mammary epithelial-specific marker (HME1) (24), and was later found to be an essential
regulator of apoptosis, cell migration, cell cycle (20, 25) and DNA damage response
involving p53 and MDM2 (26-28). In contrast to the other 14-3-3 family members, which
are able to form both homo- and heterodimers, 14-3-3σ can form only homodimers (29).
This unique characteristic implies that 14-3-3σ has exclusive functions and behaviors. 143-3σ, but not other family members, has been found to be frequently lost or decreased in
various human cancers (30)(28) and functions as a potential tumor suppressor. In
response to DNA damage, 14-3-3σ is known to be a p53 downstream target and may
2

serve as a regulator to prevent oxidative and DNA-damage stress-induced mitotic
checkpoint dysfunction (25, 28). 14-3-3σ also acts as an negative regulator of Akt (31).
As for its role in cancer, a previous report showed that there is a high frequency of
hypermethylation at the 14-3-3σ gene locus in breast cancer (32). Posttranscriptional
regulation such as ubiquitination also regulates 14-3-3σ (33). Although 14-3-3σ may play
an important role in protecting cells from DNA damage or cancer, the detailed mechanism
by which 14-3-3σ is modulated remains not well characterized.

In this study, we found that CSN6, COP1 and 14-3-3σ interact and we investigated the
role of the CSN6-COP1 axis in regulating 14-3-3σ stability. Additionally, we found that
CSN6 induced 14-3-3σ downregulation by enhancing 14-3-3σ ubiquitination, which was
abrogated when COP1 is knocked down. Further investigation of the underlying
mechanism revealed that CSN6 physically interacts with COP1 and reduces COP1mediated self-ubiquitination, thereby stabilizing COP1.

This in turn reduces COP1-

mediated 14-3-3σ ubiquitination. We previously showed that 14-3-3σ is a negative
regulator of Akt (31). Subsequently, CSN6 potentiates Akt-mediated FOXO inactivation,
which results in the transcriptional change of targets regulated by FOXO, thereby
facilitating cell survival. These data provide insight into how CSN6 overexpression can
lead to cell growth, transformation, and promote tumorigenicity. Taken together, our
studies indicate the applicability of employing CSN6-COP1 axis as a therapeutic
intervention target in cancers.
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CHAPTER 2. STATEMENT OF OBJECTIVES

Aim 1 : Determine the mechanism of CSN6 mediated 14-3-3σ degradation
Our preliminary results show that CSN6 decreases levels of 14-3-3σ. Since CSN6, as
part of the COP9 signalosome complex, is known to aid E3 ligases in ubiquitination of
target proteins, ubiquitination of 14-3-3σ is the most likely mechanism. Therefore, I shall
investigate whether CSN6 increases the ubiquitination of 14-3-3σ. To further clarify the
mechanism by which CSN6 regulates 14-3-3σ, I shall identify the E3 ligase(s) involved in
this process.

Aim 2 : Determine the role of CSN6 in the regulation of 14-3-3σtarget proteins
14-3-3σ has several down stream effects which include inhibition of Akt. The role of
CSN6 in how 14-3-3σ regulates this effect can be determined by changing CSN6
expression in the presence or absence of 14-3-3σ.

Aim 3 : Determine the biological significance of CSN6-mediated 14-3-3 σ
degradation
Our unpublished data indicate that overexpression of CSN6 increases cell proliferation
and promotes tumor growth. Since CSN6 downregulates and thus antagonizes the
activity of 14-3-3σ, I will determine the impact of 14-3-3σ on CSN6-mediated cell
proliferation and tumor promotion.

4

CHAPTER 3. MATERIALS AND METHODS

3.1. Cell culture and reagents
HCT116 p53 −/− cells were provided by Dr. Bert Vogelstein. Human 293T were cultured
in DMEM/F12 medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin
G, 100 µg/mlstreptomycin and 0.25 µg/ml amphotericin B. HCT116 cells and U2OS cells
were maintained in McCoy’s 5A medium supplemented with fetal bovine serum and
antimicrobials as mentioned above. For transient transfections, cells were transfected
with DNA using either (Lipofectamine 2000 (Invitrogen), or FuGENE HD (Roche)
reagents according to protocols of the manufacturers. Antibodies to the following epitopes
and proteins were purchased from the indicated vendors: Flag (M2 monoclonal antibody,
Sigma), Tubulin (Sigma), COP1 (Bethyl Laboratories), CSN6 (Biomol), 14-3-3σ (RDI),
Myc (mouse monoclonal 9E10, Santa Cruz Biotechnology), pAkt (Cell Signaling
Technology), Akt (Cell Signaling Technology), PARP (Cell Signaling Technology), HA
(12CA5, Roche) and Actin (Sigma).

3.2. Plasmids
pcDNA6-Myc-CSN6 and pcDNA6-Myc-COP1 were constructed in our lab by PCR.
pCMV5-Flag-14-3-3σ, Ad-β-gal, and Ad-14-3-3σ was previously described (26). FlagCSN6 (wt), 1-184 aa and 185-327 aa as well as Flag-14-3-3σ (wt), 1-161 aa and 153-248
aa were generated using standard PCR cloning methods. HA-Akt and DN-Akt were
previously described (31). FOXO luciferase reporter gene was used as described (47).
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3.3. Immunoprecipitation and immunoblotting
Total cell lysates were solubilized in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1
mM EDTA, 0.5% Nonidet P-40, 0.5% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1
mM sodium fluoride, 5 mM sodium orthovanadate and 1 µg/ml each of aprotinin,
leupeptin, and pepstatin) and processed as previously described (20). Lysates were
immunoprecipitated with indicated antibodies according to standard protocols. Proteins
were resolved by SDS-PAGE gel and proteins transferred to polyvinylidene difluoride
membranes (Millipore). Membranes were blocked with 5% nonfat milk for 1 hr at room
temperature prior to incubation with indicated primary antibodies. Subsequently,
membranes were washed and incubated for 1 hr at room temperature with peroxidaseconjugated secondary antibodies (Thermo Scientific). Following several washes,
chemiluminescent images of immunodetected bands on the membranes were recorded
on X-ray film using the enhanced chemiluminescence (ECL) system (Roche).

3.4. In vitro binding assay
Flag-CSN6 and myc-COP1 were prepared by in vitro transcription and translation using
the TNT coupled system as previously described (Promega)(20). TNT Proteins were
mixed and immunoprecipitated with anti-Myc followed by immunoblotting with anti-Flag
as described.

3.5. In vivo ubiquitination assay
HCT116 and U2OS cells were used to detect endogenous COP1 and 14-3-3σ
ubiquitination.

293T cells were transiently co-transfected with indicated plasmids to

detect exogenous 14-3-3σ ubiquitination. Forty-eight hours later, cells were treated with 5
6

µg/mL MG132 (Sigma) for 6 hr. Cells were harvested and lysed with lysis buffer (50 mM
Tris pH 7.5, 150 mM NaCl, 0.5% NP-40, 0.5% Triton X-100 and 5 mM NEM).
Ubiquitinated COP1 was immunoprecipitated with anti-COP1 (Santa Cruz Biotechnology,
Inc.)

and

immunoblotted

with

anti-HA

(Roche).

Ubiquitinated

14-3-3σ

was

immunoprecipitated with Flag (M2 monoclonal antibody, Sigma) or anti-14-3-3σ (RDI) and
immunoblotted with anti-HA (Roche). Protein complexes were then resolved by 10%
SDS-PAGE to allow observation of the polyubiquitinated COP1 or 14-3-3σ.

3.6. In vitro Ubiquitination Assay
For detection of ubiquitinated 14-3-3σ in vitro, purified 14-3-3σ proteins were incubated
with different combinations of ubiquitin (200 pmol), E1 (2 pmol), E2-UbcH5a/5b (10 pmol),
in vitro translated COP1 and ATP (2 mM) in a total volume of 50 ìl for 1 h at 37oC.
Reaction products were resolved with 8% SDS-polyacrylamide gels and probed with anti14-3-3σ or anti-GST. His-Ubiquitin (UW 8610), E1 (UW 9410) and E2 (UW 9050) were
purchased from BioMol International.

3.7. Cell lysates fractionated by Gel filtration
HCT116 and U2OS cell lysates were fractionated through Superose 6 column
(GEHealthcare) equilibrated with lysis buffer at a flow rate of 0.3ml/min. Fractions of
300μl each were collected and subjected to immunoblot.

3.8. Quantitative PCR
Primers for real-time quantitative PCR of CSN6 (5’-GCACAGACAAGTTCAAGA; 5’GTGATGGTGCCGAGGTAG),

COP1

(5’-

CTGCAACGGGCTCATCAACT;

5’-

GGCCACATTTTGTCATGTATGCT), 14-3-3σ (5’-CTCTCCTGCGAAGAGCGAAAC; 5’7

CCTCGTTGCTTTTCTGCTCAA)

14-3-3σ

CGACAGCTGCAGACCTTCAG;

target

genes—

5’-GGTTGATGCGAATACAACGGTA),

GTCAAGAGCGTGCCCTACTTC;

5’-CTTGCCACCCTCTGGATTGAG),

AGCCCATAAAACGGTCCTCAT;

5’-GAGGATGCAGAATCCCTCAG),

AAGCGGTCCCGTGGATAGA;

5’-TCCGGTATTCGCAGAAGTCC)

AAGGTGAAGGTCGGAGTCAAC;

BTG

(5’-

FOXO1

(5’-

BCL6

(5’-

BCLxL

(5’-

and GAPDH

5’-GAGTTAAAAGCAGCCCTGGTG)

were

(5’as

referenced in Primer Bank (http://pga.mgh.harvard.edu/primerbank/). Quantitative PCR
amplification of GAPDH was used for normalization. Total RNAs were extracted from cells
using Trizol (Invitrogen); 1 µg RNA was used for producing cDNA by iScript cDNA
Synthesis Kit (Bio-Rad). Quantitative real-time PCR analyses were performed using iQ
SYBR Green Super mix (Bio-Rad, 170-8882) and the iCycler iQ Real-time PCR detection
system.

3.9. Luciferase assay
A FOXO luciferase reporter gene containing a FOXO transcription factor binding site
was co-transfected with the pCMV-Myc-CSN6, pCMV-Flag-14-3-3σ or DN-Akt expressing
vectors into 293T or HCT116 cells. Luciferase activity was assayed with the dual
luciferase assay system (Promega) according to the manufacturer’s instructions.

3.10. FACS Analysis for apoptosis assay
Apoptosis was determined by two-color analysis using propidium iodide (PI) and FITCconjugated anti-Annexin V (BD Pharmingen, USA) according to the manufacturer’s
instructions. Cells were harvested and washed three times with PBS then cells were
stained with PI and FITC-conjugated anti-Annexin V and analyzed with a FACScalibur
flow cytometer.
8

3.11. Generation of stable transfectants
For generation of Myc-CSN6 overexpression stable transfectants, HCT116 and U2OS
cells were transfected with either PCDNA6 or PCDNA6-Myc-CSN6 plasmids by
electroporation (Amaxa). Forty-eight hours later, cells were selected in 8µg/ml Blasticidin
containing culture medium for 2 weeks. For generation of CSN6 knock-down stable cell
lines, HCT116 and U2OS cells were infected by lentiviral shRNA transduction particles
(Sigma, NM_006833 COPS6 MISSION shRNA lentiviral transduction particles) containing
either control shRNA or CSN6 shRNA. After infection, cells were selected with 2µg/ml
Puromycin for two weeks.

3.12. Soft agar colony formation
10,000 cells were mixed in 0.35% agarose/complete media were plated on 0.7%
agarose/complete media (bottom) layer and grown for 8 weeks. Colonies were stained
with 0.5 mg/ml p-iodonitrotetrazolium violet (Sigma) and were counted under a light
microscope (Olympus IX70). Each experiment was done at least two times in triplicate
wells.

3.13. Foci formation
1000, 2000 or 3000 cells were plated in 6-well plates and then incubated for 7−10 days.
Cells were stained with 0.005% crystal violet to visualize the colonies growing in each
well.

3.14. MTT assay
Vector control or CSN6-expressing cells were infected with Ad-β-gal (MOI = 100) or Ad9

HA-14-3-3σ (MOI =100). Cells were plated at 3000 cells/well in 96-well plates and grew in
the continued presence of selective antibiotics. Cells were counted every day using a
colorimetric 5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
for 3 hrs. Following MTT incubation, cells were lysed in 200 µL of 100% DMSO (Fisher).
Samples were then analyzed using a spectrophotomer to measure the optical density at
570 nm.

3.15. Xenograft experiment
Four to six week-old female athymic (nu/nu) mice (Experimental Radiation Oncology, M.
D. Anderson Cancer Center, Houston, TX, USA) were housed in AAALAC-approved
barrier facilities with food and water ad libitum and maintained in the animal facility at The
University of Texas M. D. Anderson Cancer Center. Mice were divided into different
groups. CSN6-expressing cells infected with Ad-β-gal (MOI = 100) or Ad-14-3-3σ (MOI
=100) were harvested and injected into the flank of each mouse. Tumor volumes were
measured and recorded from day 8 after injection. At the end of the experiment, the mice
were euthanized with CO2 and the tumors were removed and weighed.
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CHAPTER 4. RESULTS

4.1. CSN6 associates with 14-3-3σ

Others have characterized proteins that associate with the CSN complex (34)(35), and
many more remain to be identified. In Fig. 3A we show that CSN6 and 14-3-3σ coelute by
gel filtration. This led us to the hypothesis that 14-3-3σ and CSN6 may associate in
complex. Coimmunoprecipitation experiments. indeed shows their in vivo interaction (Fig.
1). We then mapped CSN6 binding region on14-3-3σ. The results showed that CSN6
binds to the C-terminus of 14-3-3σ (aa 153-248), but not the N-terminus (aa 1-161
containing dimerization domain) (Fig. 2). We also mapped 14-3-3σ binding region on
CSN6 in vitro. A GST-pull-down assay suggests that the N-terminus of CSN6 was
responsible for binding 14-3-3σ. (Fig. 3). These results demonstrate that the N-terminal
region of CSN6 binds to the C-terminal region of 14-3-3σ.

11

Figure 1. CSN6 interacts with 14-3-3σ in vivo.

Interaction of endogenous CSN6 with endogenous 14-3-3σ. Lysates of HCT116 cells
were prepared and equal amounts of cell lysates were immunoprecipitated with indicated
antibodies followed by immunoblotting with indicated antbibodies.

12

Figure 1
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Figure 2. Mapping of 14-3-3σ domain interaction with CSN6.

Mapping of CSN6 binding domains on 14-3-3σ. Myc-CSN6 and Flag-14-3-3σ (aa 1-248),
N-terminus (aa 1-161) or C-terminus (aa 153-248) was co-transfected into 293T cells.
Cell lysates were immunoprecipitated with anti-Flag and immunoblotted with anti-Myc.
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Figure 3. Mapping of the 14-3-3σ binding region within CSN6.

Mapping of 14-3-3σ binding domains on CSN6. Flag-CSN6 (aa 1-327), N-terminal (aa 1184) or C-terminal (aa 185-327) were transfected into 293T cells. Cell lysates were
subjected to GST-14-3-3σ pull-down (PD) and immunoblotted with anti-Flag antibody.
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4.2. CSN6 negatively regulates 14-3-3σ protein stability

4.2.1 CSN6 down-regulates 14-3-3σ at the post-transcriptional level
Because CSN6 interacts with 14-3-3σ, we reasoned that CSN6 has some biological
impact on 14-3-3σ. The 14-3-3σ levels were elevated when cells were infected with
CSN6-shRNA virus to perform CSN6 knockdown (Fig. 4A, left). Exogenous expression of
CSN6 also downregulated 14-3-3 σ expression (Fig. 4A, right) in a dose-dependent
manner (Fig. 4B). CSN6-mediated 14-3-3σ downregulation was suppressed by MG132, a
proteasome inhibitor, suggesting the involvement of 26S proteasome. (Fig. 5). The mRNA
levels of 14-3-3σ were not affected by CSN6 overexpression or knockdown in a real-time
quantitative PCR analysis (Fig. 6), suggesting that CSN6 downregulates 14-3-3σ at the
post-transcriptional level.

4.2.2 CSN6 increases 14-3-3σ polyubiquitination
To investigate if CSN6 can destabilize 14-3-3σ at the protein level we performed a
turnover rate experiment. Indeed, CSN6 knockdown can reduce the turnover rate of 14-33σ in the presence of the de novo protein synthesis inhibitor, cycloheximide (Fig. 7A).
Consistently, overexpression of CSN6 increases turnover rate of 14-3-3σ (Fig. 7B).
Further, we found that CSN6 increased the endogenous ubiquitination level of 14-3-3σ
(while CSN6 knockdown reduced the endogenous ubiquitination level of 14-3-3σ (Fig. 8
top). Also, increasing amounts of CSN6 shRNA antagonized poly-ubiquitination of
transfected 14-3-3σ in a dose-dependent manner (Fig. 8 bottom).

4.2.3 Downregulation of 14-3-3σ by CSN6 is not dependent on p53 expression
18

Since 14-3-3σ is regulated by p53 (25), at issue is whether CSN6-mediated 14-3-3σ
downregulation involves p53. We compared 14-3-3σ protein levels in HCT116 p53 -/cells infected with CSN6 shRNA virus or control shRNA virus and found that 14-3-3σ
protein levels were still higher in HCT116 p53 -/- cells knocked down for CSN6 versus
control virus (Fig. 9). This result suggests that downregulation of 14-3-3σ by CSN6 is not
dependent on p53 expression.
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Figure 4. CSN6 reduces the steady-state expression levels of 14-3-3σ.

A. 14-3-3σ protein level is upregulated when endogenous CSN6 expression is inhibited
with shRNA (left). Lysates of HCT116 cells infected with either CSN6 shRNA or control
shRNA were immunoblotted with anti-14-3-3σ, CSN6 or Actin antibodies. 14-3-3σ protein
level was downregulated in CSN6 overexpressing cells (right). Lysates of Myc-CSN6
overexpressing HCT116 stable transfectants and vector control transfectants were
immunoblotted with anti-14-3-3σ, CSN6, or Actin antibodies.

B. Ectopic expression of CSN6 reduces 14-3-3σ expression. 293T cells were cotransfected with the indicated expression vectors. Equal amounts of protein from cell
lysates were immunoblotted with anti-Flag, Myc, or Actin antibodies.
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Figure 5. CSN6 down-regulates 14-3-3σ through 26S proteasome pathway.

293T cells were co-transfected with the indicated plasmids. Cells were treated with or
without

proteasome

inhibitor

MG132

before

immunoblotted with anti-Flag or Tubulin antibodies.
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Figure 6. CSN6 down-regulates 14-3-3σ at the post-transcriptional level.

A. mRNA levels of 14-3-3σ are not affected by overexpression of CSN6. Real-time
quantitative PCR analysis of 14-3-3σ in 293T cells transfected with or without Myc-CSN6
showed no obvious difference in 14-3-3σ mRNA levels.

B. mRNA levels of 14-3-3σ are not affected by knockdown of CSN6 expression. Realtime quantitative PCR analysis of 14-3-3σ in HCT116 cells infected with CSN6 shRNA or
control shRNA showed no obvious difference in 14-3-3σ mRNA levels.
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Figure 7. CSN6 increases 14-3-3σ turnover rate.

A. HCT116 cells infected with either lentiviral CSN6 shRNA or control shRNA were
treated with cycloheximide (CHX) (100 µg/ml) for the indicated times. Cell lysates were
immunoblotted with anti-14-3-3σ, CSN6, or Actin antibodies. Integrated OD values of
bands at each time point were measured using a densitometer. Levels of 14-3-3σ at time
zero were set at 100%. Remaining 14-3-3σ is indicated graphically (right).

B. 293T cells were co-transfected with the indicated expression vectors. Forty-eight hours
after transfection, the cells were treated with cycloheximide (CHX) (100 µg/ml) for the
indicated times. Cell lysates were immunoblotted with anti-Flag, Myc, or Actin antibodies.
Integrated OD values of bands at each time point were measured using a densitometer.
Levels of 14-3-3σ at time zero were set at 100%. 14-3-3σ remaining is indicated
graphically.
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Figure 8. CSN6 increases 14-3-3σ poly-ubiquitination.

CSN6 increases endogenous 14-3-3σ polyubiquitination (top). Indicated or transfected
cells were treated with MG132 for four hours before harvesting. Polyubiquitinated 14-33σ was immunoprecipitated with anti-14-3-3σ and immunoblotted with anti-HA. Equal
amounts of cell lysates were immunoblotted with anti-CSN6 or Actin.

Knockdown of CSN6 reduces poly-ubiquitination of exogenous 14-3-3σ (bottom). 293T
cells were co-transfected with indicated plasmids and increasing amounts of CSN6
shRNA.

Cells

were

treated

with

MG132

for

four

hours

before

harvesting.

Polyubiquitinated 14-3-3σ was immunoprecipitated with anti-Flag and immunoblotted with
anti-HA. Equal amounts of cell lysates were immunoblotted with anti-CSN6 or Actin
antibodies.
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Figure 9. Downregulation of 14-3-3σ by CSN6 is not dependent on p53 expression.

HCT116 p53 -/- cells were infected with either CSN6 shRNA or luciferase shRNA. Equal
amounts of cell lysates were immunoblotted with anti-14-3-3σ, CSN6, or Actin antibodies.
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4.3. CSN6 regulates 14-3-3σ protein stability through E3 ubiquitin ligase COP1

4.3.1 Gel filtration and elution profiles analysis of CSN6, COP1 and 14-3-3σ
The COP9 signalosome (CSN) and COP1 are required for the dark-dependent
degradation

of

the

transcription

factor

HY5

(12),

a

positive

regulator

of

photomorphogenesis in plants. Although CSN is required for proper functioning of COP1,
a direct interaction between CSN and COP1 has not been characterized. To investigate
this possible direct interaction, we analyzed HCT116 and U2OS cell lysates separated
with gel filtration columns. Lysate fractions were analyzed by SDS-PAGE and
immunoblotting. Fig. 10 shows that COP1, CSN6, and 14-3-3σ are present in the
fractions corresponding to the molecular size of the COP9 holocomplex (between 400693 kDa), suggesting the interaction of COP1 and 14-3-3σ with the COP9 signalosome.
These observations led us to investigate the functional relevance of the interaction of
CSN6 and COP1.

4.3.2 CSN6 interacts with COP1 and elevates the steady-state protein levels of COP1 at
the post-transcriptional level
Fig. 11 shows that CSN6 associates with COP1 endogenously as assayed by co-ip and
an In vitro binding assay confirms that CSN6 directly binds to COP1. To address the
significance of the CSN6 and COP1 interaction, we examined the impact of CSN6 on
COP1 levels and noted that the steady-state level of COP1 increased when CSN6 was
overexpressed (Fig. 12A). The mRNA levels of COP1 were not affected by CSN6
expression in a real-time quantitative PCR analysis (Fig. 12B), suggesting that CSN6 upregulates COP1 at the post-transcriptional level.
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4.3.3 CSN6 reduces poly-ubiquitination of COP1
Further, the turnover rate of endogenous COP1 was reduced in CSN6 overexpressing
cells in a cycloheximide chase assay (Fig. 13). We also examined the effect of CSN6 on
COP1 ubiquitination. As expected, polyubiquitinated COP1 was reduced in CSN6
overexpressing cells compared with control cells (Fig. 14). Taken together, these findings
demonstrate that CSN6 increases COP1 stability through inhibition of ubiquitin-mediated
COP1 proteasomal degradation.
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Figure 10. Gel filtration and elution profiles analysis of CSN6, COP1 and 14-3-3σ.

The distributions of CSN6, 14-3-3σ, and COP1 were analyzed by gel filtration
chromatography. Immunoblots of the fractions for indicated proteins are shown in both
HCT116 (A) and U2OS (B) cells. Molecular weight markers are indicated.
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Figure 11. CSN6 interacts with COP1.

A. Endogenous COP1 interacts with endogenous CSN6. Lysates of U2OS cells were
prepared and equal amounts of cell lysates immunoprecipitated with either rabbit IgG or
anti-COP1 antibodies followed by immunoblotting with anti-CSN6 antibody (left panel).

B. COP1 is shown to interact with CSN6 in vitro (right panels). Myc-COP1 and FlagCSN6 cDNAs were transcribed and translated in vitro. COP1 and CSN6 proteins were
incubated overnight and immunoprecipitated with anti-Myc followed by immunoblotting
with anti-Flag.
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Figure 12. Overexpression of CSN6 elevates the steady-state protein levels of
COP1 at the post-transcriptional level.

A. Lysates of Myc-CSN6 overexpressing U2OS stable transfectants or vector control
transfectants were immunoblotted with anti-COP1, CSN6, or Actin antibodies.

B. mRNA levels of COP1 are not affected by overexpression of CSN6. Real-time
quantitative PCR analysis of COP1 in Myc-CSN6 overexpressing U2OS stable
transfectants or vector control transfectants showed no obvious difference in COP1
mRNA levels.
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Figure 13. CSN6 decreases COP1 turnover rate.

Myc-CSN6 overexpressing U2OS stable transfectants and vector control transfectants
were treated with cycloheximide (CHX) (100 µg/ml) for indicated times. Cell lysates were
immunoblotted with anti-COP1, Myc, or Actin antibodies. Integrated OD values of bands
at each time point were measured using a densitometer. Levels of COP1 at time zero
wwere set at 100%. COP1 remaining is indicated graphically.
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Figure 14. CSN6 reduces poly-ubiquitination of COP1.

Myc-CSN6 overexpressing U2OS stable transfectants or vector control transfectants
were transfected with HA-Ubiquitin. Cells were treated with MG132 four hours before
harvesting. Polyubiquitinated COP1 was immunoprecipitated with anti-COP1 and
immunoblotted

with

anti-HA antibodies.

Equal

immunoblotted with anti-CSN6 or Actin antibodies.
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4.4. COP1 is required for CSN6-mediated 14-3-3σ degradation

4.4.1 COP1 interacts with 14-3-3σ and Knockdown of COP1 expression reduces polyubiquitination of 14-3-3σ
Given that CSN6 associates with COP1 and that COP1 coelutes with 14-3-3σ in gel
filtration assays (Fig. 10), we reasoned that COP1 could be involved in CSN6-mediated
14-3-3σ ubiquitination. Indeed, 14-3-3σ was able to associate with COP1 endogenously
as assayed by co-ip (Fig. 15). Increasing amounts of COP1 shRNA also increased
steady-state levels of 14-3-3σ (Fig. 16A). Consistently, COP1 shRNA reduced the
turnover rate of 14-3-3σ in 293T cells (Fig. 17) and COP1 shRNA reduced
polyubiquitinated 14-3-3σ levels in a dose-dependent manner (Fig. 18).

4.4.2 Knockdown of COP1 expression in CSN6 overexpressing cells increases 14-3-3σ
expression through reducing CSN6-mediated poly-ubiquitination of 14-3-3σ
COP1 shRNA also increased endogenous levels of 14-3-3σ in HCT116 cells (Fig. 16B)
and the mRNA levels of 14-3-3σ were not significantly affected by COP1 shRNA,
suggesting that COP1 shRNA upregulates 14-3-3σ at the post-transcriptional level (Fig.
16C). In light of the observation that CSN6 stabilized COP1 and negatively regulated 143-3σ, we further evaluated the impact of COP1 on CSN6-mediated 14-3-3σ polyubiquitination. We found that increasing amounts of COP1 shRNA in HCT116 cells
overexpressing CSN6 led to increased 14-3-3σ steady-state expression (Fig. 19A).
Levels of CSN6-mediated 14-3-3σ poly-ubiquitination were also compromised by
increasing amounts of COP1 shRNA (Fig. 19B).
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4.4.3 COP1 induces the ubiquitination of 14-3-3σ in an in vitro ubiquitination assay
As expected, COP1 also efficiently increased the ubiquitination level of 14-3-3σ in an in
vitro ubiquitination assay (Fig. 20). These results suggested that COP1 is a novel E3
ligase for 14-3-3σ whose ubiquitination is also mediated by CSN6.
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Figure 15. COP1 interacts with 14-3-3σ in vivo.

Endogenous COP1 interacts with endogenous 14-3-3σ. Lysates of HCT116 cells were
prepared and equal amounts of cell lysates immunoprecipitated with either mouse IgG or
14-3-3σ followed by immunoblotting with anti-COP1 antibody.
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Figure 16. Knockdown of COP1 expression elevates the steady-state levels of 14-33σ at the post-transcriptional level.

A. 14-3-3σ protein level is upregulated when endogenous COP1 expression is inhibited
with shRNA. 293T cells were co-transfected with indicated plasmids and increasing
amounts of COP1 shRNA. Equal amounts of cell lysates were immunoblotted with antiFlag, COP1, or Actin antibodies.

B. 14-3-3σ protein level was upregulated when endogenous CSN6 expression was
inhibited by shRNA. Lysates of HCT116 cells transfected with increasing amounts of
CSN6 shRNA were immunoblotted with anti-14-3-3σ, COP1, or Actin antibodies.

C. mRNA levels of 14-3-3σ are not significantly affected by knockdown of COP1
expression. Real-time quantitative PCR analysis of 14-3-3σ in HCT116 cells transfected
with COP1 shRNA or control shRNA showed no significant difference in 14-3-3σ mRNA
levels.
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Figure 17. Knockdown of COP1 expression reduces 14-3-3σ turnover rate.

293T cells were transfected with the indicated expression vectors. Forty-eight hours after
transfection, the cells were treated with cycloheximide (CHX) (100 µg/ml) for the
indicated times. Cell lysates were immunoblotted with anti-Flag, COP1, or Actin
antibodies. Integrated OD values of bands at each time point were measured using a
densitometer. The level of 14-3-3σ at time zero was set at 100%. 14-3-3σ remaining is
indicated graphically.
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Figure 18. Knockdown of COP1 expression reduces poly-ubiquitination of 14-3-3σ.

293T cells were co-transfected with indicated plasmids and increasing amounts of COP1
shRNA. Cells were treated with MG132 four hours before harvest, and polyubiquitinated
14-3-3σ immunoprecipitated with anti-Flag followed by immunoblotting with anti-HA.
Equal amounts of cell lysates were immunoblotted with anti-COP1 or Actin antibodies.
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Figure 19. Knockdown of COP1 expression in CSN6 overexpressing cells
increases 14-3-3σ expression through reducing CSN6-mediated poly-ubiquitination
of 14-3-3σ.

A. Knockdown of COP1 expression in CSN6 overexpressing cells increases the steadystate expression of 14-3-3σ. Lysates of Myc-CSN6 overexpressing HCT116 cells
transfected with increasing amounts of COP1 shRNA were immunoblotted with anti-14-33σ, COP1, or Actin antibodies.

B. Knockdown of COP1 expression in CSN6 overexpressing cells reduced the polyubiquitination of 14-3-3σ. Myc-CSN6 overexpressing HCT116 cells were co-transfected
with indicated plasmids and increasing amounts of COP1 shRNA. Cells were treated with
MG132 four hours before harvest. Polyubiquitinated 14-3-3σ was immunoprecipitated
with anti-14-3-3σ and immunoblotted with anti-HA antibodies. Equal amounts of cell
lysates were immunoblotted with anti-COP1 or Actin antibodies.
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Figure 20. COP1 induces the ubiquitination of 14-3-3σ in an in vitro ubiquitination
assay.

GST-14-3-3σ was incubated with or without Myc-COP1 which was prepared with in vitro
translation (TNT) in the presence of E1, E2, His-Ubiquitin and ATP as indicated.
Ubiquitinated 14-3-3σ was detected by immunoblotting with anti-14-3-3σ or anti-GST
antibodies.
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4.5.

CSN6-14-3-3σ

axis

regulates

Akt-mediated

cell

survival

and

FOXO

transcriptional activity

4.5.1 CSN6 has impact on Akt activity
Akt has been implicated in the control of cell survival. For example, mice with targeted
disruption of the akt1 gene are more sensitive to apoptosis-inducing stimuli (36). Because
14-3-3σ suppresses Akt activity (31), we first examined whether knockdown of CSN6
could suppress Akt activity and inhibit Akt-mediated cell survival. To address this, we
used U2OS cells infected with CSN6 shRNA virus or control virus and found that Akt
activity was suppressed when CSN6 was knocked down versus control (Fig. 21A) as
indicated by reduced phosphorylation of Akt at Serine 473. In order to determine whether
lower Akt activity in CSN6 knockdown cells leads to apoptosis, cells were analyzed for
Annexin V staining at day 4 after serum starvation. Knockdown of CSN6 demonstrated
significant increases in both early apoptotic (Annexin V staining 41.9%, at right bottom
quadrant) and late apoptotic cells (Annexin V staining 13.6% at right upper quadrant)
compared to control cells (18.0% and 5.4%, respectively) (Fig. 21B). Cells were also cotransfected with constitutively active Akt (HA tagged-Akt) or treated with LY294002 (PI3K
inhibitor). As expected, LY294002 have added the impact on shCSN6-mediated
apoptosis in the absence of serum (Fig. 21B). In contrast, the exogenous HA tagged-Akt
prevented the potentiation of CSN6 shRNA in serum starvation-mediated cell death (Fig.
21B), suggesting that the CSN6-Akt axis is involved in cell survival. Also, cells were
serum starved and analyzed for the presence of the cleaved form of PARP, an apoptosis
marker. CSN6 knockdown cells showed more PARP cleavage compared with control
cells (Fig. 21C). Taken together, these results suggest that knockdown of CSN6 resulted
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in enhanced apoptotic cell death when the cells were cultured in serum free medium and
that loss of cell viability was likely to be due to the suppression of Akt activity.

4.5.2 CSN6 suppresses FOXO target gene expression
Akt

has

been

reported

to

suppress

FOXO

transcriptional

activity

through

phosphorylation (37, 38). Since CSN6 downregulates 14-3-3σ expression and thus
enhances Akt activity, we next examined the impact of CSN6 on the Akt-mediated
suppression of FOXO transcriptional activity. As expected, Akt activity in CSN6
overexpressing HCT116 cells was higher than in control cells (Fig. 22A). We then
examined the target gene expression of FOXO transcription factors under the condition of
CSN6 overexpression. In Fig. 22B we show that FOXO transcriptional targets, such as
BTG, FOXO1 and BCL6, were decreased in HCT116 CSN6-overexpressing cells (Fig.
22B). Consistently, BCL-xL, which is repressed by BCL6, was upregulated in CSN6
overexpressing HCT116 cells reflecting the impact of CSN6-mediated suppression of
BCL6 (Fig. 22B).

4.5.3 14-3-3σ and DN-Akt antagonizes CSN6-mediated FOXO transcriptional activity
To demonstrate the link between CSN6, 14-3-3σ, Akt and FOXO, we analyzed the
functional link by employing a FOXO-responsive luciferase reporter gene assay. We
found that CSN6 expression impaired FOXO transcriptional activity (Fig. 23), and this
effect was reversed by increased expression of Flag-14-3-3σ or DN-Akt (Fig. 23). Taken
together, overexpression of CSN6 leads to downregulation of 14-3-3σ, which in turn
activates Akt kinase, resulting in the suppression of FOXO transcriptional activity.
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Figure 21. CSN6 has impact on Akt activity.

A. Knockdown of CSN6 expression suppresses Akt activity. Lysates of U2OS cells
infected with either CSN6 shRNA or control shRNA were immunoblotted with antiphospho-Akt, Akt, 14-3-3σ, CSN6, or Actin antibodies.

B. Knockdown of CSN6 accelerates apoptosis induced by serum starvation. U2OS cells
infected with either CSN6 shRNA or control shRNA were transfected with either empty
vector or HA-Akt. Cells were cultured in 0% FBS containing either DMSO or 10 µM of
LY294002 (LY) for four days. Binding of Annexin V and uptake of propidium iodide were
analyzed by flow cytometry. Left panel, representative analysis of apoptotic cells. The
lower left quadrant contains the viable population of cells, the lower right quadrant
contains early apoptotic cells, the upper left quadrant contains necrotic cells and the
upper right quadrant contains late apoptotic cells. The mean of three data sets was taken
and the values shown from the corresponding quadrant (right panel).

C. Knockdown of CSN6 expression leads to PARP cleavage. U2OS cells infected with
either CSN6 shRNA or control shRNA were cultured in 0% FBS for indicated times. Cell
lysates were immunoblotted with anti-PARP or anti-Actin antibodies.
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Figure 22. CSN6 suppresses FOXO target gene expression.

A. Overexpression of CSN6 enhances Akt activity. Lysates of Myc-CSN6 overexpressing
HCT116 stable transfectants or vector control transfectants were immunoblotted with antiphospho-Akt, Akt, CSN6, or Actin antibodies.

B. CSN6 suppresses FOXO target gene expression. mRNA levels of the indicated FOXO
target genes were determined by quantitative RT-PCR in HCT116 cells stably expressing
either Myc-CSN6 or vector control.
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Figure 23. 14-3-3σ and DN-Akt antagonizes CSN6-mediated FOXO transcriptional
repression.

HCT116 (A) and 293T (B) cells were co-transfected with a FOXO-responsive luciferase
reporter and the indicated expression vectors. Relative luciferase activity is shown as a
bar graph.
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4.6. CSN6-14-3-3σ axis regulates cell growth and tumorigenicity.

66

4.6.1 14-3-3σ inhibits CSN6-mediated cell proliferation
Since CSN6 downregulates and thus antagonizes the activity of 14-3-3σ, we reasoned
that CSN6 would have a role in cell proliferation and anchorage-independent growth. In
Fig. 24 we show that indeed CSN6 overexpression facilitates cell growth. Since CSN6
can mediate 14-3-3σ inhibition, we sought to examine the growth effect of expressing 143-3σ in terms of cell proliferation, foci formation, and anchorage-independence in CSN6overexpressing cells. We found that CSN6 overexpressing HCT116 cells infected with
Ad-14-3-3σ showed inhibition of cell proliferation, foci formation, and anchorageindependent growth when compared with the Ad-β-gal control (Fig. 24).

4.6.2 14-3-3σ suppresses tumorigenesis of CSN6-overexpressing cells
Our unpublished data indicate that overexpression of CSN6 promotes tumor growth
(39). Because 14-3-3σ suppresses CSN6-mediated cell proliferation and anchorageindependent growth, we next examined the impact of 14-3-3σ on CSN6-mediated tumor
promotion. We observed that xenografted tumor volume was significantly decreased in
Ad-14-3-3σ-treated mice compared with Ad-β-gal-treated mice (Fig. 25A). Further, the
average excised tumor weight per mouse in the Ad-β-gal-treated group (507 mg) was
higher than in the Ad-14-3-3σ-treated group (310 mg) (Fig. 25B). Tumors obtained from
this study were fixed, embedded in paraffin, and sections were examined.
Immunohistochemistry staining indicated that cell proliferation marker, Ki67, was reduced
in tumors from Ad-14-3-3σ-treated mice when compared with the control group, while the
signal intensity of apoptotic marker, cleaved Caspase 3, was increased in the Ad-14-33σ-treated group when compared with the Ad-β-gal-treated group (Fig. 25D). Together,
these data illustrate that the COP9 signalosome subunit 6-14-3-3σ axis is deregulated
when CSN6 is overexpressed, and this promotes cell growth and tumorigenicity.
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Significantly, 14-3-3σ expression can correct the abnormalities mediated by CSN6
expression.

Figure 24. 14-3-3σ inhibits CSN6-mediated cell proliferation.

68

A. Myc-CSN6 overexpressing HCT116 stable transfectants and vector control
transfectants were plated in 96-well plates and the number of live cells estimated by MTT
assay every day for a total of 3 days (left, top panel). Results are expressed as OD570.
Myc-CSN6 overexpressing HCT116 cells were infected with Ad-β-gal or Ad-HA-14-3-3σ
(leftbottom panel). Error bars represent 95% confidence intervals. 14-3-3σ antagonizes
CSN6-mediated foci formation.

B. Myc-CSN6 overexpressing HCT116 stable transfectants and vector control
transfectants were analyzed for foci formation (Middle, top). Myc-CSN6 overexpressing
HCT116 cells infected with Ad-β-gal or Ad-HA-14-3-3σ were plated at low density and
allowed to form foci (middle, bottom).

C. Myc-CSN6 overexpressing HCT116 stable transfectants, vector control transfectants
or Myc-CSN6 overexpressing HCT116 cells infected with Ad-β-gal or Ad-HA-14-3-3σ
were analyzed for soft agar colony formation (right, top). Average numbers of colonies
per field were scored. Error bars represent 95% confidence intervals.

Figure 24
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Figure 25. 14-3-3σ suppresses tumorigenesis of CSN6-overexpressing cells.
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A. Myc-CSN6 overexpressing HCT116 stable transfectants were infected with Ad-14-3-3σ
or Ad-β-gal. Cells were harvested and subcutaneously injected into the flank of female
nude mice. Tumor volumes were monitored for 31 days. Tumor growth curves are shown
(left); error bars represent 95% confidence intervals.

B. C. Tumors were exised at the end of the study and tumor weights from each group
measured (B). Error bars represent 95% confidence intervals. Representative tumors
from each group (C).

D. Tumor sections were stained with anti-Ki67 and anti-cleaved Caspase 3. Percentage
positive signal is plotted as a bar graph. Error bars represent 95% confidence intervals.

Figure 25
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Figure 26. Model of the impact of the CSN6-COP1 axis in regulating 14-3-3σ
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signaling.

Figure 26
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CHAPTER 5. DISCUSSION
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In mammalian cells, COP1 regulates various cellular targets, including stressresponsive transcription factors, p53 tumor suppressor (13), c-JUN (14-16), acetyl-coA
carboxylase (17), TORC2 (18), MVP (40) and nucleosome remodeling factor MTA1 (19),
suggesting its versatile functions. Many COP1 associated proteins remain to be
characterized. In this study, our results indicate that COP1 binds and is a novel E3 ligase
for 14-3-3σ.
The known proteins interacting with 14-3-3σ, include Cdk’s (20, 41), p53 (26) and Efp
(estrogen inducible finger protein) (42), and all play important roles in tumorigenesis. We
find here that CSN6 is a new 14-3-3σ-associating protein (Fig. 1) and is important in
promoting cancer growth (Fig. 25) through its binding and degradation of 14-3-3σ (Fig. 8).
We further determined that CSN6 regulates 14-3-3σ posttransccriptionally by enhancing
14-3-3σ ubiquitination. CSN6 does not have the conserved RING or HECT domains
found in well-characterized E3 ligases. Therefore, at issue is how CSN6 causes 14-3-3σ
downregulation. Thus we searched for potential ligases that could associate with the
COP9 signalosome and found that the COP1 E3 ligase is a potential candidate. It is
wothwhile to point out that as an E3 ligase for p53, COP1 drives the ubiquitination and
proteasomal degradation of p53, thereby maintaining low steady-state levels of p53 in
unstressed cells (43). In this way, COP1 may antagonize the activity of positive p53
regulators such as 14-3-3σ, which can stabilize p53 by reducing p53 ubiquitination level.
Also, COP1 is downregulated in response to DNA damage (44), while 14-3-3σ protein
level is elevated by DNA damage (25). Together, it is conceivable that COP1 and 14-3-3σ
may have a functional relationship. Indeed, we observed for the first time that CSN6
recruits RING containing COP1 to degrade 14-3-3σ. This is based on the observation that
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CSN6-mediated 14-3-3σ degradation is compromised when COP1 is knocked down with
shRNA. Importantly, CSN6 not only associates with COP1 but also prevents COP1’s selfubiquitination, adding yet another layer of regulation.
Although Efp, another RING containing protein, was previously characterized as an E3
ligase for 14-3-3σ (42), it remains to be studied whether CSN6 also recruits Efp to
degrade 14-3-3σ. Interestingly, Efp has another activity and seems to serve as an E3
ligase to add ISG15 (15 Kd protein encoded by an interferon stimulated gene) for 14-33σ-ISGylation (33, 45), but the role of this type of modification in terms of 14-3-3σ protein
degradation remains unclear. We previously showed that 14-3-3σ is a negative regulator
of Akt (31). Consistent with this, we found that CSN6 can downregulate the expression of
14-3-3σ and lead to Akt activation. The observation that CSN6 increases the activity of
Akt (Fig. 21) is very intriguing. This is the first discovery that links the COP9 signalosome
with Akt activation. We have shown that CSN6 is involved in 14-3-3σ-mediated Akt
inhibition, which in turn antagonizes FOXO-meditated transcriptional activity for proapoptotic genes (Fig. 22, 23). Our mechanistic studies of CSN6-mediated 14-3-3σ
downregulation explains how CSN6 can activate Akt in our proposed model (Fig. 26).
This study shows that CSN6 positively regulates Akt and promotes Akt-mediated cell
survival to prevent apoptosis. Clearly, the CSN6-Akt link will be an important molecular
target for rational cancer therapy. Our primary breast cancer studies showed that CSN6 is
amplified in 75% of primary breast cancers (39). Also, COP1 and 14-3-3σ inversely
correlate in primary pancreatic and breast cancer (46). Together, it demonstrates that the
CSN6-COP1-14-3-3σ-axis is deregulated in cancer. Here, we show that adenoviral gene
delivery of 14-3-3σ can inhibit tumorigenicity mediated by CSN6 activity in cancer models
(Fig. 25). Also, similar results were observed in that 14-3-3σ can compromise
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tumorigenicity mediated by COP1 activity in xenograft cancer models (46). In conclusion,
since both CSN6 and COP1 are involved in degrading 14-3-3σ, promoting cell survival
and increasing tumorigenicity, targeting the CSN6-COP1 axis may be a useful therapeutic
strategy for cancer intervention.
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